Dr. Reddy's Laboratories Limited has informed the Exchange about elevation of Mr. Sandeep Khandelwal as a Senior Management Personnel.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's Board meeting held on May 12, 2026 approved five items: (1) Re-appointment of Dr. K P Krishnan as Independent Director for a second five-year term from January 2027 to January 2032; (2) Appointment of Mr. Srikanth Velamakanni (Co-Founder & CEO of Fractal, an AI company) as an Independent Director for five years from July 2026; (3) Appointment of Deloitte Haskins & Sells, LLP as Statutory Auditors for a five-year term starting from the 42nd AGM; (4) Re-appointment of Sagar & Associates as Cost Auditors for FY 2026-27; and (5) Elevation of Mr. Sandeep Khandelwal (Global Generics India Head) as a Senior Management Personnel and member of the Management Council, effective May 12, 2026. Sandeep has driven the India business from Rs 2,300 crore to Rs 7,000 crore over seven years, improving market rank from 16th to 9th.
The additions of two new Independent Directors and a Big 4 auditor (Deloitte) signal strong governance intent. Sandeep Khandelwal's elevation is positive — he leads a $750 million India operation and has demonstrated strong growth delivery, which could support further upside in the domestic generics business.